keyword
MENU ▼
Read by QxMD icon Read
search

Stent thrombosis

keyword
https://www.readbyqxmd.com/read/28105561/the-rise-and-fall-of-anticoagulation-with-bivalirudin-during-percutaneous-coronary-interventions-a-review-article
#1
REVIEW
Constantinos Andreou, Christos Maniotis, Michael Koutouzis
Bivalirudin is a direct thrombin inhibitor used during percutaneous coronary intervention (PCI). Treatment with bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) reduced bleeding complications, but resulted in higher rates of ischemic events, including acute stent thrombosis in ST segment elevation myocardial infarction (STEMI) patients. Thus, it may be considered a reasonable alternative antithrombotic agent in patients at high risk of bleeding undergoing PCI. However its superiority over heparin alone is questioned particularly in the era of novel antiplatelet agents and transradial PCI...
January 19, 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/28104210/9-month-clinical-and-angiographic-outcomes-of-the-cobra-polyzene-f-nanocoated-coronary-stent-system
#2
Donald E Cutlip, Kirk N Garratt, Victor Novack, Mark Barakat, Perwaiz Meraj, Luc Maillard, Andrejs Erglis, Rajiv Jauhar, Jeffrey J Popma, Robert Stoler, Sigmund Silber
OBJECTIVES: The aim of this study was to assess the safety and effectiveness of the COBRA Polyzene-F NanoCoated Coronary Stent System (CeloNova Biosciences, San Antonio, Texas) for the treatment of de novo coronary artery lesions. BACKGROUND: Polyzene-F-coated coronary stents have shown reduced thrombogenicity and inflammation in preclinical studies. METHODS: Patients with de novo coronary artery lesions meeting eligibility criteria were enrolled in a nonrandomized, prospective clinical trial...
January 23, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28104208/first-in-human-evaluation-of-a-novel%C3%A2-polymer-free-drug-filled-stent-angiographic-ivus-oct-and-clinical-outcomes-from%C3%A2-the%C3%A2-revelution-study
#3
Stephen G Worthley, Alexandre Abizaid, Ajay J Kirtane, Daniel I Simon, Stephan Windecker, Sandeep Brar, Ian T Meredith, Sharad Shetty, Ajay Sinhal, Alexandra Popma Almonacid, Daniel Chamié, Akiko Maehara, Gregg W Stone
OBJECTIVES: This study sought to assess the safety and effectiveness of the drug-filled stent (DFS) (Medtronic, Santa Rosa, California) in the treatment of patients with coronary artery disease. BACKGROUND: Polymer-free drug-eluting stents have the potential to improve clinical outcomes and facilitate shorter durations of dual antiplatelet therapy. The polymer-free DFS is made from a trilayered continuous wire with an outer cobalt chromium layer, a middle tantalum layer, and an inner lumen coated with sirolimus...
January 23, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28104206/randomized-multicenter-trial-investigating%C3%A2-angiographic-outcomes-of%C3%A2-hybrid-sirolimus-eluting-stents-with%C3%A2-biodegradable-polymer-compared-with%C3%A2-everolimus-eluting-stents-with-durable%C3%A2-polymer-in-chronic-total-occlusions-the-prison-iv-trial
#4
Koen Teeuwen, René J van der Schaaf, Tom Adriaenssens, Jacques J Koolen, Pieter C Smits, José P S Henriques, Paul H M J Vermeersch, R Melvyn Tjon Joe Gin, Bastiaan E Schölzel, Johannes C Kelder, Jan G P Tijssen, Pierfrancesco Agostoni, Maarten J Suttorp
OBJECTIVES: The aim of this study was to investigate the efficacy and safety of the hybrid ultrathin-strut sirolimus-eluting stent (SES) with biodegradable polymer compared with the thin-strut everolimus-eluting stent (EES) with durable polymer in successfully recanalized chronic total occlusions (CTOs). BACKGROUND: The introduction of drug-eluting stents revolutionized the treatment of CTOs. However, limited data are available on new-generation drug-eluting stents with biodegradable polymer in CTOs...
January 23, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28098065/the-treatment-of-post-thrombotic-syndrome
#5
Karina Schleimer, Mohammad Esmaeil Barbati, Alexander Gombert, Volker Wienert, Jochen Grommes, Houman Jalaie
BACKGROUND: Post-thrombotic syndrome (PTS) arises in 20-50% of patients who have sustained a deep vein thrombosis and markedly impairs their quality of life. METHODS: This review is based on pertinent publications retrieved by a selective literature search in PubMed and the Cochrane Library, and on the guidelines of the German Societies of Phlebology and Vascular Surgery (Deutsche Gesellschaft für Phlebologie, Deutsche Gesellschaft für Gefässchirurgie). RESULTS: The treatment options are conservative treatment with compression and patient exercises, endovascular recanalization with stent angioplasty, and open bypass surgery of the iliac obstructions...
December 16, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28097197/early-coronary-thrombosis-without-st-segment-elevation-following-repair-of-acute-aortic-dissection
#6
Davide Carino, Francesco Nicolini, Giorgio Romano, Matteo Ricci, Tiziano Gherli
Acute coronary thrombosis after emergent surgery for acute Type A aortic dissection is a rare event that can remain undiagnosed in absence of typical electrocardiogram readings. We report a case of left anterior descending artery thrombosis without ST-segment elevation three days after surgical repair, which was successfully treated with angioplasty and stenting.
August 2016: Aorta (Stamford, Conn.)
https://www.readbyqxmd.com/read/28096181/long-term-8-10%C3%A2-years-outcomes-after-biodegradable-polymer-coated-biolimus-eluting-stent-implantation
#7
Masanobu Ohya, Shunsuke Kubo, Akimune Kuwayama, Katsuya Miura, Takenobu Shimada, Hidewo Amano, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Harumi Katoh, Tsuyoshi Goto, Kazushige Kadota
OBJECTIVE: Efficacy and safety data on biodegradable polymer-coated biolimus-eluting stent (BP-BES) are currently limited to 5 years. We evaluated longer term (8-10 years) clinical and angiographic outcomes after BP-BES implantation. METHODS: Between 2005 and 2008, 243 patients (301 lesions) underwent BP-BES implantation. The primary clinical outcome measure was defined as any target lesion revascularisation (TLR). Absolute serial angiographic studies without any concomitant TLR within 2 years after the procedure were performed in 55 patients (65 lesions) at postprocedure, mid-term (within 1 year), late term (between 1 and 2 years) and very late term (beyond 2 years)...
January 17, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28096040/calcium-a-predictor-of-interventional-treatment-failure-across-all-fields-of-cardiovascular-medicine
#8
EDITORIAL
Alessio Mattesini, Carlo Di Mario
In this substudy of the ADAPT-DES trial Généreux et al. compared two years outcomes according to the presence or absence of coronary artery calcification (CAC) as assessed by coronary angiography. Coronary calcification was an independent predictor of interventional treatment failure and a higher incidence of both ischemic events and bleeding. The cohort with CAC was older with a higher prevalence of risk factors and comorbidities and an increased anatomical complexity of the target lesions, explaining only in part the worse outcome of the CAC population that persisted at multivariate analysis...
January 10, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28089999/impact-of-impaired-renal-function-in-patients-with-severely-calcified-coronary-lesions-treated-with-orbital-atherectomy
#9
Michael S Lee, Evan Shlofmitz, Gentian Lluri, Richard A Shlofmitz
OBJECTIVES: We evaluated the clinical outcomes of patients with chronic kidney disease (CKD) who underwent orbital atherectomy for severe coronary artery calcification (CAC) prior to stent implantation. BACKGROUND: Percutaneous coronary intervention (PCI) of lesions with severe CAC is associated with increased rates of adverse clinical events. Patients with CKD are at increased risk for atherosclerotic cardiovascular disease, including vascular calcification, and have worse outcomes after PCI...
January 15, 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28089137/a-comparison-of-cangrelor-prasugrel-ticagrelor-and-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-a-network-meta-analysis
#10
Peter C Westman, Michael J Lipinski, Rebecca Torguson, Ron Waksman
BACKGROUND: Newer P2Y12 inhibitors have more rapid onset of platelet inhibition compared with clopidogrel, especially the intravenous P2Y12 inhibitor cangrelor. Direct comparisons between cangrelor and oral P2Y12 inhibitors ticagrelor and prasugrel do not exist. Thus, we performed a network meta-analysis to directly and indirectly compare different P2Y12 inhibitors in patients undergoing percutaneous coronary intervention (PCI). METHODS: MEDLINE/PubMed and ClinicalTrials...
October 21, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28081310/a-simple-risk-score-in-acute-st-elevation-myocardial-infarction-modified-acef-age-creatinine-and-ejection-fraction-score
#11
Arzu Kalaycı, Vecih Oduncu, Çetin Geçmen, Selim Topcu, Can Yücel Karabay, İbrahim Akın İzgi, Cevat Kırma
BACKGROUND/AIM: The aim of this study was to evaluate if the modified ACEF (age, creatinine, and ejection fraction) score is a predictor of major adverse cardiac and cerebrovascular events during 1 year of follow-up in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). MATERIALS AND METHODS: We retrospectively enrolled 1632 consecutive patients who were admitted to our emergency department diagnosed with STEMI within 12 h of chest pain and treated with primary PCI...
December 20, 2016: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28078379/chitosan-sodium-tetradecyl-sulfate-hydrogel-characterization-and-preclinical-evaluation-of-a-novel-sclerosing-embolizing-agent-for-the-treatment-of-endoleaks
#12
Fatemeh Zehtabi, Vincent Dumont-Mackay, Ahmed Fatimi, Antony Bertrand-Grenier, Hélène Héon, Gilles Soulez, Sophie Lerouge
PURPOSE: To compare the efficacy of an embolization agent with sclerosing properties (made of chitosan and sodium tetradecyl sulfate, CH-STS) with a similar embolization agent but without sclerosing properties (made of chitosan, CH) in treating endoleaks in a canine endovascular aneurysm repair model. METHODS: Two chitosan-based radiopaque hydrogels were prepared, one with STS and one without STS. Their rheological, injectability, and embolizing properties were assessed in vitro; afterwards, their efficacy in occluding endoleaks was compared in a canine bilateral aneurysm model reproducing type I endoleaks (n = 9 each)...
January 11, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28069734/life-threatening-simultaneous-acute-stent-thrombosis-associated-with-anaphylactic-shock-due-to-contrast-material
#13
Akira Sato, Daiki Akiyama, Tomoya Hoshi, Kazutaka Aonuma
No abstract text is available yet for this article.
January 9, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28067198/outcomes-of-patients-treated-with-durable-polymer-platinum-chromium-everolimus-eluting-stents-a-meta-analysis-of-randomized-trials
#14
Salvatore Cassese, Gjin Ndrepepa, Robert A Byrne, Sebastian Kufner, Erion Xhepa, Antoinette de Waha, Tobias Rheude, Roisin Colleran, Daniele Giacoppo, Yukinori Harada, Karl-Ludwig Laugwitz, Heribert Schunkert, Massimiliano Fusaro, Adnan Kastrati
AIMS: The durable-polymer platinum-chromium everolimus-eluting stent (PtCr-EES) is a new- generation drug-eluting stent (DES) with a platinum-enriched metallic platform developed to improve the percutaneous treatment of patients with coronary artery disease. We sought to investigate the performance of durable-polymer PtCr-EES versus other new-generation DES. METHODS AND RESULTS: We undertook a meta-analysis of trials, in which patients receiving percutaneous coronary intervention (PCI) were randomly assigned to durable-polymer PtCr-EES versus other new-generation DES (other DES)...
January 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28066582/in-stent-restenosis-and-thrombosis-due-to-metal-hypersensitivity-implications-for-kounis-syndrome
#15
EDITORIAL
Ioanna Koniari, Nicholas G Kounis, George Hahalis
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28062139/efficacy-and-safety-of-everolimus-and-zotarolimus-eluting-stents-versus-first-generation-drug-eluting-stents-in-patients-with-diabetes-a-meta-analysis-of-randomized-trials
#16
Chirag Bavishi, Usman Baber, Sadik Panwar, Stefania Pirrotta, George D Dangas, Pedro Moreno, Jacqueline Tamis-Holland, Annapoorna S Kini, Samin K Sharma
INTRODUCTION: Patients with diabetes and coronary artery disease remain at high risk for adverse cardiovascular events after percutaneous coronary intervention. The efficacy and safety of the various drug-eluting stents (DES) in patients with diabetes is unclear. METHODS: Randomized controlled trials comparing first-generation DES [paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] with everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in diabetic patients were systematically searched...
December 27, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28058211/organ-transplantation-and-drug-eluting-stents-perioperative-challenges
#17
REVIEW
Aparna Dalal
Patients listed for organ transplant frequently have severe coronary artery disease (CAD), which may be treated with drug eluting stents (DES). Everolimus and zotarolimus eluting stents are commonly used. Newer generation biolimus and novolimus eluting biodegradable stents are becoming increasingly popular. Patients undergoing transplant surgery soon after the placement of DES are at increased risk of stent thrombosis (ST) in the perioperative period. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel and ticagrelor is instated post stenting to decrease the incident of ST...
December 24, 2016: World Journal of Transplantation
https://www.readbyqxmd.com/read/28057284/very-late-scaffold-thrombosis-of-bioresorbable-vascular-scaffold-systematic-review-and%C3%A2-a%C3%A2-meta-analysis
#18
Toshiaki Toyota, Takeshi Morimoto, Hiroki Shiomi, Yusuke Yoshikawa, Hidenori Yaku, Yugo Yamashita, Takeshi Kimura
OBJECTIVES: This study sought to compare the 2-year outcomes between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic drug-eluting stent (EES). BACKGROUND: The occurrence of very late stent/scaffold thrombosis (VLST) of BVS beyond 1 year after implantation is an increasing concern. METHODS: We conducted a meta-analysis of 24 studies (BVS: n = 2,567 and EES: n = 19,806) reporting the 2-year outcomes of BVS and/or EES to compare the risk of BVS versus EES for stent/scaffold thrombosis (ST) and target lesion failure (TLF) in 7 comparative studies (3 randomized and 4 observational), and to estimate the pooled incidence rates of ST and TLF including additional 17 single-arm studies...
January 9, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28056809/is-the-concomitant-use-of-clopidogrel-and-proton-pump-inhibitors-still-associated-with-increased-adverse-cardiovascular-outcomes-following-coronary-angioplasty-a-systematic-review-and-meta-analysis-of-recently-published-studies-2012-2016
#19
Pravesh Kumar Bundhun, Abhishek Rishikesh Teeluck, Akash Bhurtu, Wei-Qiang Huang
BACKGROUND: Controversies were previously observed with the concomitant use of clopidogrel and Proton Pump Inhibitors (PPIs), especially omeprazole, following coronary angioplasty. Even though several studies showed no interaction between clopidogrel and PPIs, questions have been raised about the decrease in antiplatelet effects of clopidogrel with PPIs. A previously published meta-analysis showed concomitant use of clopidogrel and PPIs to be associated with higher adverse cardiovascular outcomes...
January 5, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28054461/comparative-efficacy-of-sirolimus-eluting-stents-and-paclitaxel-eluting-stents-in-east-asian-versus-non-east-asian-patients-a-systematic-review-meta-analysis
#20
Rui Zhao, Qianwei Lu, Rui Yang, Jianlin Du, Songbo Deng, Qiang She
BACKGROUND: First-generation drug-eluting stents - such as the sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) - have become attractive options for percutaneous coronary intervention (PCI) and are still widely used in Asia. However, the effect of East Asian ethnicity on their efficacy remains unclear. METHODS: Pubmed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials comparing the efficacy of the Cypher SES and Taxus PES...
January 5, 2017: Cardiovascular Therapeutics
keyword
keyword
40437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"